Treatment
Selumetinib clinical trials
We’re tracking 9 recruiting studies that include Selumetinib, each written for real people, not researchers, below.
Recruiting studies
- NCT05253131RecruitingPhase 2
Selumetinib plus durvalumab for advanced sarcoma
This Phase 2 study tests whether selumetinib and durvalumab can slow or shrink certain advanced sarcomas. It’s for adults with disease that has come back, progressed, or can’t be safely removed with surgery.
Birmingham, AlabamaAges 18–99 - NCT06502171RecruitingPhase 1
Cabozantinib and selumetinib for plexiform neurofibromas
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
Birmingham, AlabamaAges 16 years+ - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Birmingham, AlabamaAges 2–21 - NCT03326310RecruitingPhase 1
Selumetinib plus azacitidine for high-risk blood cancers
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
Chicago, IllinoisAges 18 years+ - NCT06188741RecruitingPhase 2
Selumetinib to prevent tumor growth in NF1 children
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
Birmingham, AlabamaAges 1–8 - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Birmingham, AlabamaAges Any age - NCT06735820RecruitingPhase 1/Phase 2
MEK and MDM2 inhibitors for NF1-related tumors
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
Washington D.C., District of ColumbiaAges 18 years+ - NCT02813135RecruitingPhase 1/Phase 2
Targeted cancer treatment chosen by a tumor’s genetic findings
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
CopenhagenAges Up to 18 years - NCT06360406Recruiting
Real-world study of Koselugo (selumetinib) in South Korea
This study looks at how patients with certain conditions are doing while taking Koselugo (selumetinib) in real life. It's a way to gather information about the treatment's effectiveness and safety outside of a controlled clinical trial.
BusanAges 3–99
What Selumetinib is being studied for
Conditions with recruiting Selumetinib studies.
Common questions
- Are there clinical trials studying Selumetinib?
- Yes. Clin2 currently lists 9 recruiting studies that include Selumetinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Selumetinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Selumetinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Selumetinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.